Monopar Therapeutics 10-Q Filing

From the Filing

0001437749-25-034617.txt : 20251113 0001437749-25-034617.hdr.sgml : 20251113 20251113080052 ACCESSION NUMBER: 0001437749-25-034617 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20250930 FILED AS OF DATE: 20251113 DATE AS OF CHANGE: 20251113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 251475491 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 10-Q 1 mnpr20250930_10q.htm FORM 10-Q mnpr20250930_10q.htm 0001645469 Monopar Therapeutics Inc. false --12-31 Q3 2025 0.001 0.001 40,000,000 40,000,000 6,662,930 6,662,930 6,102,560 6,102,560 7,857,568 81,932 0 no 715,315 476,758 0 0 0 0 6,662,930 0.00 25.00 25.01 50.00 50.01 75.00 75.01 100.00 1.42 false false false false Cash equivalents as of June 30, 2025, and December 31, 2024, represent the fair value of the Company’s investments in money market accounts and U.S. Treasury securities with maturities at the date of purchase of three months or less. 248,381 options vest as follows: options to purchase 8,270 shares of the Company’s common stock vesting immediately upon the grant date; options to purchase 2,000 shares of the Company’s common stock vesting monthly over one year; options to purchase 51,143 shares of the Company’s common stock vesting quarterly over one year; options to purchase 186,968 shares of the Company’s common stock vesting 6/48ths on the six-month anniversary of the vesting commencement date and 1/48th per month thereafter. In aggregate, there were 120,941 restricted stock units granted during the nine months ended September 30, 2025, of which 6,002 restricted stock units vested immediately upon the grant date and 114,939 restricted stock units vest 6/48ths on the six-month anniversary of the vesting commencement date and 3/48ths per quarter thereafter. Forfeited options represent unvested shares and vested, unexercised and expired shares related to employee terminations.? Information pertaining to number of shares outstanding and per share data gives retroactive effect to a 1 for 5 reverse stock split that became effective on August 12, 2024. Forfeitures only include known forfeitures to date as the Company accounts for forfeitures as they occur due to a limited history of forfeitures. Cash equivalents as of September 30, 2025, and December 31, 2024, represent the fair value of the Company’s investments in money market accounts and U.S. Treasury securities with maturities at the date of purchase of three months or less. 0001645469 2025-01-01 2025-09-30 xbrli:shares 0001645469 2025-10-31 thunderdome:item iso4217:USD 0001645469 2025-09-30 0001645469 2024-12-31 iso4217:USD xbrli:shares 0001645469 2025-07-01 2025-09-30 0001645469 2024-07-01 2024-09-30 0001645469 2024-01-01 2024-09-30 0001645469 us-gaap:CommonStockMember 2024-12-31 0001645469 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001645469 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001645469 us-gaap:RetainedEarningsMember 2024-12-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmploy